Bright Minds Biosciences Inc(DRUG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DRUG Bright Minds Biosciences Inc

Market Closed 11-22 16:00:00 EST

35.33

+2.95

+9.11%

盘后33.34

-1.99-5.63%

19:55 EST

High36.72	Low31.35	Vol241.62K
Open31.41	D1 Closing32.38	Amplitude16.58%
Mkt Cap245.49M	Tradable Cap94.36M	Total Shares6.95M
T/O8.43M	T/O Rate9.05%	Tradable Shares2.67M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"DRUG","market":"US","secType":"STK","nameCN":"Bright Minds Biosciences Inc","latestPrice":35.33,"timestamp":1732309200000,"preClose":32.38,"halted":0,"volume":241617,"hourTrading":{"tag":"盘后","latestPrice":33.34,"preClose":35.33,"latestTime":"19:55 EST","volume":666,"amount":22933.1396,"timestamp":1732323345356},"delay":0,"floatShares":2670899,"shares":6948489,"eps":-0.632749,"marketStatus":"Market Closed","change":2.95,"latestTime":"11-22 16:00:00 EST","open":31.41,"high":36.72,"low":31.35,"amount":8428303.582236,"amplitude":0.165843,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.632749,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732525200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":32.38,"preHourTrading":{"tag":"盘前","latestPrice":31.0461,"preClose":32.38,"latestTime":"09:13 EST","volume":183,"amount":5873.509440000001,"timestamp":1732284780411},"postHourTrading":{"tag":"盘后","latestPrice":33.34,"preClose":35.33,"latestTime":"19:55 EST","volume":666,"amount":22933.1396,"timestamp":1732323345356},"volumeRatio":1.5642013142789974},"requestUrl":"/m/hq/s/DRUG/tweets","defaultTab":"tweets","newsList":[{"id":"2485491026","title":"Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2485491026","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485491026?lang=en_us&edition=fundamental","pubTime":"2024-11-21 22:00","pubTimestamp":1732197600,"startTime":"0","endTime":"0","summary":"- Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data-. NEW YORK, Nov. 21, 2024  -- Bright Minds Biosciences Inc. , a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system  disorders, is proud to announce two upcoming presentations at the American Epilepsy Society 2024 Annual Meeting in Los Angeles, December 6-10, 2024.The Company’s presentation details are as follows:. On September 12th, Bright Minds Biosciences announced the initiation of the BREAKTHROUGH Study, an open-lab","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/JwJgcnB4S_b8a2M99WSNBw--~B/aD0xMTY7dz0xNTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/735c1b21b81298fe7e2944c74905c12e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/JwJgcnB4S_b8a2M99WSNBw--~B/aD0xMTY7dz0xNTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/735c1b21b81298fe7e2944c74905c12e"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bright-minds-biosciences-present-data-140000193.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","DRUG"],"gpt_icon":0},{"id":"2481966423","title":"CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY","url":"https://stock-news.laohu8.com/highlight/detail?id=2481966423","media":"PR Newswire","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481966423?lang=en_us&edition=fundamental","pubTime":"2024-11-07 06:21","pubTimestamp":1730931660,"startTime":"0","endTime":"0","summary":"NASHVILLE, Tenn., Nov. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. , a specialty pharmaceutical company, announced today that the United States  Food and Drug Administration  granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy . Cumberland is completing the FIGHT DMD trial, a multicenter, double-blind, placebo-controlled Phase II study investigating the pharmacokinetics, safety and efficacy of once daily oral Ifetroban in patients with DMD. Results will be announced later this year.\"For Duchenne muscular dystrophy, a devastating genetic disorder affecting young boys, securing both Orphan Drug and Rare Pediatric Disease Designations for Ifetroban from the FDA is a critical step forward,\" said A.J. Kazimi, chief executive officer of Cumberland Pharmaceuticals. \"These designations not only recognize the urgent need for effective treatments but also provide vital supp","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Z8HjfTeavBqH4AOjpvidSw--~B/aD04Mzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/d6491f4600abd2c969a7073e33e75676","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Z8HjfTeavBqH4AOjpvidSw--~B/aD04Mzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/d6491f4600abd2c969a7073e33e75676"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cumberland-pharmaceuticals-receives-fda-orphan-222100374.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cumberland-pharmaceuticals-receives-fda-orphan-222100374.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CPIX","BK4557","BK4024","RARE","BK4139","FOR","DRUG"],"gpt_icon":1},{"id":"2481267296","title":"Bright Minds Biosciences Secures $35 Million Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2481267296","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481267296?lang=en_us&edition=fundamental","pubTime":"2024-11-06 19:30","pubTimestamp":1730892613,"startTime":"0","endTime":"0","summary":"Bright Minds Biosciences has successfully closed a $35 million private placement, attracting significant participation from major healthcare investors such as Cormorant Asset Management and RA Capital Management. The funds raised will be directed towards advancing the company’s drug development programs focused on neurological and psychiatric disorders. This strategic move underscores Bright Minds’ commitment to delivering breakthrough therapies and enhancing its position in the biotech sector.For further insights into TSE:DRUG stock, check out TipRanks’ Stock Analysis page.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CelDdPDqWVkcG2SiBC__kg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/c4f6c07e08d4829fbea65fa26099a197","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CelDdPDqWVkcG2SiBC__kg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/c4f6c07e08d4829fbea65fa26099a197"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/bright-minds-biosciences-secures-35-113013163.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bright-minds-biosciences-secures-35-113013163.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DRUG","BK4139"],"gpt_icon":0},{"id":"2481605135","title":"Massachusetts psychedelics legalization initiative poised to fail","url":"https://stock-news.laohu8.com/highlight/detail?id=2481605135","media":"seekingalpha","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481605135?lang=en_us&edition=fundamental","pubTime":"2024-11-06 14:55","pubTimestamp":1730876108,"startTime":"0","endTime":"0","summary":"Yarygin  A Massachusetts ballot question that would allow adults to grow, use, and possess many psychedelic substances appears poised for defeat. With 80% of precincts reporting, opponents of the measure are leading 56.7% to 43.3%. The substances that would be legalized under the proposal are psilocybin and psilocin, which are found in \"magic mushrooms,\" as well as dimethyltryptamine, mescaline, and ibogaine.  Oregon and Colorado already allow the use of some psychedelic substances. Psychedelic drug developers: Mind Medicine , Compass Pathways , Cybin , Atai Life Sciences , Enveric Bio , Revive Therapeutics , Bright Minds Biosciences , GH Research , Clearmind Medicine .","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1363506971/image_1363506971.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1363506971/image_1363506971.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4253295-massachusetts-psychedelics-legalization-initiative-poised-fail","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["ATAI","CMPS","QID","BK4168","ENVB","RVVTF",".IXIC","TQQQ","DRUG","MNQmain","BK4139","DRUG.AU","QLD","GHRS","SQQQ","PSQ","NQmain","BK4547","CMND","BK4539","BK4007","MNMD","CYBN"],"gpt_icon":1},{"id":"2481555619","title":"Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2481555619","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481555619?lang=en_us&edition=fundamental","pubTime":"2024-11-05 03:41","pubTimestamp":1730749260,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, Nov. 04, 2024  -- Bright Minds Biosciences Inc.    announces that further to its news release of October 18, 2024, the Company has closed a non-brokered private placement of 1,612,902 common shares in the capital of the Company  at a price of USD$21.70 per Share for aggregate gross proceeds of USD$35,000,000 .The Company is pleased to announce that the Offering included participation from Cormorant Asset Management, RA Capital Management, Perceptive Advisors, Janus Henderson Investors, Vivo Capital, AcutaCapital Partners, Schonfeld Strategic Advisors, and other healthcare investors. The Company intends to use the aggregate gross proceeds from the Offering for research and development related to its drug development programs, and general working capital.All securities issued in connection with the Offering are subject to a statutory hold period of four months and one day following the date of issuance in accordance with applicable Canadian securities laws. N","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/JwJgcnB4S_b8a2M99WSNBw--~B/aD0xMTY7dz0xNTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/735c1b21b81298fe7e2944c74905c12e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/JwJgcnB4S_b8a2M99WSNBw--~B/aD0xMTY7dz0xNTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/735c1b21b81298fe7e2944c74905c12e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bright-minds-biosciences-closes-us-194100677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","DRUG"],"gpt_icon":1},{"id":"2479208152","title":"Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2479208152","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479208152?lang=en_us&edition=fundamental","pubTime":"2024-10-30 13:07","pubTimestamp":1730264820,"startTime":"0","endTime":"0","summary":"Bright Minds Biosciences' BMB-101, a 5-HT2C receptor agonist, shows promise in treating drug-resistant epilepsy, with favorable Phase 1 safety and efficacy data.The company's proprietary platform targ","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1623196944/image_1623196944.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1623196944/image_1623196944.jpg"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4730739-bright-minds-biosciences-stock-bmb-101-trials-unlock-epilepsy-market-potential","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["DRUG"],"gpt_icon":1},{"id":"2478265433","title":"Keurig Dr Pepper makes an energizing M&A move","url":"https://stock-news.laohu8.com/highlight/detail?id=2478265433","media":"seekingalpha","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478265433?lang=en_us&edition=fundamental","pubTime":"2024-10-24 23:29","pubTimestamp":1729783772,"startTime":"0","endTime":"0","summary":"Parradee KietsirikulKeurig Dr Pepper (NASDAQ:KDP) traded 5.4% lower on Thursday after missing revenue estimates with its Q3 earnings report. However, the company also announced an M&A play that has some analysts intrigued. The beverage company announced the acquisition of Ghost Energy","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1403479106/image_1403479106.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1403479106/image_1403479106.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4200628-keurig-dr-pepper-makes-an-energizing-ma-move","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BK4505","MNQmain","BK4566","QLD","BK4535","BK4588","IE00BJTD4N35.SGD",".IXIC","LU1989763690.USD","KDP","LU1989763427.SGD","BK4585","NQmain","BK4177","QID","IE00BJTD4V19.USD","TQQQ","SQQQ","PSQ","DRUG"],"gpt_icon":0},{"id":"2477655382","title":"Steven Cohen's Strategic Acquisition of Bright Minds Biosciences Inc Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2477655382","media":"GuruFocus","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477655382?lang=en_us&edition=fundamental","pubTime":"2024-10-24 22:14","pubTimestamp":1729779241,"startTime":"0","endTime":"0","summary":"Overview of the Recent Transaction On October 16, 2024, Steven Cohen (Trades, Portfolio), through Point72 Asset Management, made a significant new investment in the biotechnology sector by purchasing ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gurufocus.com/news/2565506/steven-cohens-strategic-acquisition-of-bright-minds-biosciences-inc-shares","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"gurufocus_highlight","symbols":["DRUG","BK4139"],"gpt_icon":1},{"id":"2477863045","title":"Bright Minds, Firefly Team Up to Analyze Data of Phase 2 Study of BMB-101 to Treat Epilepsy; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2477863045","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477863045?lang=en_us&edition=fundamental","pubTime":"2024-10-21 21:45","pubTimestamp":1729518308,"startTime":"0","endTime":"0","summary":"Bright Minds Biosciences (DRUG) said Monday it is collaborating with Firefly Neuroscience (AIFF) to provide an analysis of the electroencephalogram data in its phase 2 trial assessing the safety, tole","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AIFF","TISI","DRUG"],"gpt_icon":1},{"id":"2477804345","title":"Bright Minds and Firefly Neuroscience collaborate for EEG data in receptor agonist study","url":"https://stock-news.laohu8.com/highlight/detail?id=2477804345","media":"seekingalpha","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477804345?lang=en_us&edition=fundamental","pubTime":"2024-10-21 21:11","pubTimestamp":1729516272,"startTime":"0","endTime":"0","summary":"JuSun/iStock via Getty Images  Bright Minds Biosciences  partners with Firefly Neuroscience  to analyze EEG data for mid-stage receptor agonist study, a Phase 2 Trial of BMB-101, in adults with Absence Epilepsy and Developmental Epileptic Encephalopathy. DRUG up 24% premarket, while AIFF up about 10%. Bright","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1248262649/image_1248262649.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1248262649/image_1248262649.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4183235-bright-minds-and-firefly-neuroscience-collaborate-for-eeg-data-in-receptor-agonist-study","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["NQmain","BK4139","BK4134","QLD","MNQmain","QID","PSQ",".IXIC","TQQQ","SQQQ","AIFF","DRUG"],"gpt_icon":0},{"id":"2477852937","title":"Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2477852937","media":"GlobeNewswire","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477852937?lang=en_us&edition=fundamental","pubTime":"2024-10-21 20:30","pubTimestamp":1729513800,"startTime":"0","endTime":"0","summary":"NEW YORK AND VANCOUVER, British Columbia, Oct.  21, 2024  (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ: DRUG), a biotechnology company focused on developing ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/21/2966191/0/en/Bright-Minds-Biosciences-and-Firefly-Neuroscience-to-Collaborate-After-the-BREAKTHROUGH-Study-A-Phase-2-Trial-of-BMB-101-in-Absence-Epilepsy-and-Developmental-Epileptic-Encephalopa.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WRD","AIFF","BK4139","BK4134","DRUG"],"gpt_icon":1},{"id":"2477858348","title":"U.S. exceptionalism is now driving markets - if only this jinx can be avoided","url":"https://stock-news.laohu8.com/highlight/detail?id=2477858348","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477858348?lang=en_us&edition=fundamental","pubTime":"2024-10-21 18:42","pubTimestamp":1729507320,"startTime":"0","endTime":"0","summary":"BNP Paribas and UBS Global Wealth Management point to U.S. economy's resilience. Bad news, America - the Economist, on its cover, just said the U.S. economy is the envy of the world.Brett Donnelly of Spectra Markets did a comprehensive study of magazine covers three years ago and found that Economist covers in particular were contrarian indicators, in both directions.Then again it's not just the Economist talking of U.S. exceptionalism.Strategists at BNP Paribas say that will be the theme as policymakers - and market participants - descend on Washington D.C. for the annual International Monetary Fund and World Bank meetings this week.They note that the Atlanta Fed's Q3 nowcast for GDP growth is up to 3.4% annualized, while their own nowcast for the eurozone is for 0.3% growth on a quarter-on-quarter basis. Measuring the two regions on an apples-to-apples basis, the U.S. is still expected to triple eurozone growth in the third quarter.The U.S. economy's resilience also was the driving f","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["US7Y.BOND","SG9999014005.SGD","LU1059921491.USD","LU0417517546.SGD","US2Y.BOND","IE00BJTD4V19.USD","LU2133065610.SGD","LU1435385759.SGD","IE00BJJMRY28.SGD","LU1430594728.SGD","US5Y.BOND","TSLA","LU0868494708.USD","BK4566","HUM","US30Y.BOND","IE00BFXG1179.USD","IE00BJTD4N35.SGD","LU1429558221.USD","GME","LU0320765489.SGD","BK4196","LU1261432733.SGD","BK4154","LU2326559502.SGD","KVUE","US6M.BOND","AAPL","IE00B7KXQ091.USD","US912797HE00.BOND","IE0004445015.USD","DRUG","LU0058720904.USD","US10Y.BOND","TSM","BK4533","CI","LU0390134368.USD","NVDA","PLTR","US3Y.BOND","SG9999014021.USD","MCD","AMZN","LU1244550577.SGD","BK4550","BK4585","IE00BFSS8Q28.SGD","LU1244550221.USD","LU0208291251.USD","IE0002270589.USD","BK4534","BK4504","US12M.BOND","NIO","BK4581","LU0238689110.USD","DJT"],"gpt_icon":1},{"id":"2476058766","title":"FDA is said to see “path forward” for ecstasy-based drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2476058766","media":"seekingalpha","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476058766?lang=en_us&edition=fundamental","pubTime":"2024-10-19 21:40","pubTimestamp":1729345202,"startTime":"0","endTime":"0","summary":"Lykos Therapeutics, whose lead asset, midomafetamine capsules (MDMA), failed to win the FDA nod in August, said that the regulator has indicated a path forward for the Ecstasy-based drug, which, if ap","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4178859-fda-is-said-to-see-path-forward-for-ecstasy-based-drug","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["MNMD","DRUG","BK4139","ENVB","BK4007","BK4547","CMPS"],"gpt_icon":1},{"id":"2476130712","title":"Sector Update: Health Care Stocks Advance Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2476130712","media":"MT Newswires Live","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476130712?lang=en_us&edition=fundamental","pubTime":"2024-10-19 03:48","pubTimestamp":1729280903,"startTime":"0","endTime":"0","summary":"Health care stocks were higher late Friday afternoon, with the NYSE Health Care Index up 0.3% and the Health Care Select Sector SPDR Fund (XLV) rising 0.4%.The iShares Biotechnology ETF (IBB) increase","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0208291251.USD","ORGS","CVS.AU","BK4588","LU0072461881.USD","LU1571399168.USD","BK4504","BK4550","LU0061475181.USD","LU0162691827.USD","LU0070302665.USD","LU1699723380.USD","BK4196","BK4139","IE00BZ1G4Q59.USD","BK4581","IE00BSNM7G36.USD","BK4007","XLV","IE00BFXG1179.USD","LU1059921491.USD","IE00BKVL7J92.USD","IBB","CVS","LU0006061336.USD","LU0211331839.USD","LU0320765489.SGD","DRUG","BK4585","SNY"],"gpt_icon":1},{"id":"2476299232","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2476299232","media":"MT Newswires Live","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476299232?lang=en_us&edition=fundamental","pubTime":"2024-10-19 02:18","pubTimestamp":1729275516,"startTime":"0","endTime":"0","summary":"Bright Minds Biosciences  shares skyrocketed 164% amid heavy trading after the company said on Friday that it launched a private placement of common shares at $21.70 apiece.More than 20.3 million shares traded intraday compared with a daily average of about 2.3 million.Joint Stock Company Kaspi.kz  said it signed a definitive agreement to acquire 65.41% of the total outstanding Class A and Class B shares of D-Market Electronic Services & Trading , also known as Hepsiburada, from founder Hanzade Dogan and other shareholders for about $1.13 billion.Shares of Kaspi jumped 7%, with intraday trading volume at over 390,000 compared with a daily average of about 355,000.US Cellular  said Friday it has agreed to sell some of its spectrum licenses to telecommunications giant Verizon Communications  for $1 billion in cash, subject to potential adjustments. US Cellular said it obtained approval for the Verizon deal from its 82% shareholder, Telephone and Data Systems .Shares of Telephone and Data","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0942090050.USD","USM","LU1861220207.SGD","BK4132","LU1051769294.HKD","LU0651946864.USD","VZ","BK4581","LU0985481810.HKD","LU1585245621.USD","LU0320765646.SGD","LU1430594728.SGD","LU1571399168.USD","LU0868494708.USD","LU1051768304.USD","HEPS","LU0303823156.USD","LU0098860793.USD","LU0868494617.USD","LU0321505439.SGD","LU1481012133.USD","LU0225771236.USD","LU2384288077.EUR","LU0321505868.SGD","LU0196876865.USD","LU1621768115.EUR","DRUG","LU1066051225.USD","LU0231793349.USD","KSPI","LU0390136736.USD","LU1162221912.USD","BK4115","BK4166","LU0306807586.USD","BK4550","BK4539","BK4585","LU0390137544.SGD","LU1621768206.USD","LU1699723380.USD","BK4515","BK4559","LU1066051498.USD","TDS","LU0251143458.SGD","LU1861217088.USD","LU1366192091.USD","LU0651947912.USD"],"gpt_icon":1},{"id":"2476257397","title":"US-Listed Shares of Bright Minds Biosciences Jump 200% After $35 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2476257397","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476257397?lang=en_us&edition=fundamental","pubTime":"2024-10-18 23:02","pubTimestamp":1729263735,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241018:nFWN3LU0OL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DRUG"],"gpt_icon":0},{"id":"2476232809","title":"Sector Update: Health Care Stocks Steady Pre-Bell Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2476232809","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476232809?lang=en_us&edition=fundamental","pubTime":"2024-10-18 21:12","pubTimestamp":1729257126,"startTime":"0","endTime":"0","summary":"Health care stocks were steady pre-bell Friday as the iShares Biotechnology ETF  and Health Care Select Sector SPDR Fund  were inactive recently.CVS Health  shares fell by over 7% after the company said it expects Q3 adjusted earnings per share of $1.05 to $1.10, including charges to record premium deficiency reserves of around $1.1 billion that lowered its Q3 adjusted EPS by $0.63.Orgenesis  shares tumbled by over 33% after the company said in a regulatory filing that Nasdaq decided to delist the company's shares as it was not in compliance with listing requirements and trading will be suspended on Monday.Bright Minds Biosciences  shares surged past 64% after the company launched a private placement of common shares at a price of $21.70 per share.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CVS","LU1699723380.USD","LU0061475181.USD","LU0072461881.USD","IE00BZ1G4Q59.USD","DRUG","IBB","LU0162691827.USD","LU1059921491.USD","LU0208291251.USD","IE00BSNM7G36.USD","LU0006061336.USD","CVS.AU","LU0320765489.SGD","LU1571399168.USD","LU0211331839.USD","BK4581","LU0070302665.USD","BK4196","IE00BKVL7J92.USD","ORGS","XLV","BK4504","BK4588","BK4139","BK4585","BK4550"],"gpt_icon":1},{"id":"2476231470","title":"Bright Minds rebounds after $35M private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2476231470","media":"seekingalpha","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476231470?lang=en_us&edition=fundamental","pubTime":"2024-10-18 20:51","pubTimestamp":1729255862,"startTime":"0","endTime":"0","summary":"JuSun/iStock via Getty ImagesAfter two days of declines, shares of Bright Minds Biosciences (NASDAQ:DRUG) bounced back in the premarket on Friday with a ~48% rise after the psychedelic drug developer announced a private placement to raise up to $35M in gross proceeds. In","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1248262649/image_1248262649.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1248262649/image_1248262649.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4174739-bright-minds-stock-gains-post-private-placement","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["PSQ","NQmain",".IXIC","BK4139","TQQQ","MNQmain","DRUG","SQQQ","QLD","QID"],"gpt_icon":0},{"id":"2476233143","title":"Bright Minds Biosciences Launches $35 Million Private Placement; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2476233143","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476233143?lang=en_us&edition=fundamental","pubTime":"2024-10-18 20:14","pubTimestamp":1729253665,"startTime":"0","endTime":"0","summary":"Bright Minds Biosciences  said Friday it launched a private placement of common shares at a price of $21.70 per share.The biotechnology company also said it has a right to issue pre-funded warrants at $21.70 apiece, with each warrant being exercisable into one pre-funded warrant share for $0.001.Bright Minds Biosciences said it expects aggregate gross proceeds of up to $35 million, which will be used for research and development related of drug development programs, as well as general capital purposes.Shares of the company were up 33% in recent Friday premarket activity.Price: 28.89, Change: +7.19, Percent Change: +33.13","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","DRUG"],"gpt_icon":1},{"id":"2476287495","title":"Bright Minds Biosciences sells shares at $21.70 in private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2476287495","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476287495?lang=en_us&edition=fundamental","pubTime":"2024-10-18 19:37","pubTimestamp":1729251479,"startTime":"0","endTime":"0","summary":"Bright Minds Biosciences (DRUG) announced a non-brokered private placement of common shares at a price of $21.70 per share. The aggregate gross pro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bright-minds-biosciences-sells-shares-at-21-70-in-private-placement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bright-minds-biosciences-sells-shares-at-21-70-in-private-placement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","DRUG"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.brightmindsbio.com","stockEarnings":[{"period":"1week","weight":-0.1081},{"period":"1month","weight":-0.2483},{"period":"3month","weight":33.9802},{"period":"6month","weight":31.0454},{"period":"1year","weight":24.3443},{"period":"ytd","weight":23.7063}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.3088},{"period":"ytd","weight":0.2529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.083026},{"month":2,"riseRate":0,"avgChangeRate":-0.168482},{"month":3,"riseRate":0,"avgChangeRate":-0.281262},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.050307},{"month":5,"riseRate":0.666667,"avgChangeRate":0.142657},{"month":6,"riseRate":0,"avgChangeRate":-0.154404},{"month":7,"riseRate":1,"avgChangeRate":0.255985},{"month":8,"riseRate":0.333333,"avgChangeRate":0.120025},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.170472},{"month":10,"riseRate":0.333333,"avgChangeRate":12.882876},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.050494},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.164582}],"exchange":"NASDAQ","name":"Bright Minds Biosciences Inc","nameEN":"Bright Minds Biosciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Bright Minds Biosciences Inc(DRUG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Bright Minds Biosciences Inc(DRUG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Bright Minds Biosciences Inc,DRUG,Bright Minds Biosciences Inc股票,Bright Minds Biosciences Inc股票老虎,Bright Minds Biosciences Inc股票老虎国际,Bright Minds Biosciences Inc行情,Bright Minds Biosciences Inc股票行情,Bright Minds Biosciences Inc股价,Bright Minds Biosciences Inc股市,Bright Minds Biosciences Inc股票价格,Bright Minds Biosciences Inc股票交易,Bright Minds Biosciences Inc股票购买,Bright Minds Biosciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Bright Minds Biosciences Inc(DRUG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Bright Minds Biosciences Inc(DRUG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction